SAGE-ONF
20.7.2022 02:02:07 CEST | Business Wire | Press release
Sage-ONF, a synthetic leather supplier boasting 29 years of experience in design, development, manufacturing and sales, launches serial production of Silicone Synthetic leather. The Sage-ONF plant has begun manufacturing the Silicone Synthetic leather in Shanghai, China.
As consumers continue to demand greater sustainability commitments, this new venture extends Sage-ONF’s heritage of sustainability by delivering Silicone Synthetic leather as an innovative petroleum-free, non-carbon-based product solution for today’s mobility interiors. With a steadfast conviction to continuous innovation and earth-friendly business practices, this new material avoids DMF and plasticizer usage.
“Bringing together our core competencies as Sage-ONF, we bridge the gap between consumer expectations and industry capabilities to provide alternatives that are both environmentally friendly and bolster animal welfare around the globe,” said Robbie Lv, General Manager of Sage-ONF.
Sage and ONF bring 74 years in the automotive interiors business and a deep understanding of cultural trends and design preferences to deliver unparalleled luxury and a soft hand feel that consumers demand for interior mobility needs. Beyond the touch, consumers can have confidence in their interior’s longevity and cleanability—simply wipe stains with a damp cloth to remove them.
However, experience proves that interiors must be tough enough to tackle mile after mile with a super resilient resistance to extreme temperatures . Using UV, hydrolysis, cold crack and flame tests, Sage-ONF ensures long-lasting interiors that enhance the consumer mobility experience. While many claim superiorities in luxury or in sustainability, Sage-ONF exceeds expectations in both realms by using non-solvent and plasticizer-free techniques to create an opulent silicone with ultra-low VOCs.
“By keeping our product, process and mission as our guide, we are pleased to create a silicone synthetic leather that meets the demanding needs of the mobility interior without leather’s known fragility, extra weight, environmental impact and short lifespan,” said Mark Brezenski, Vice President – Asia at Sage, an Asahi Kasei company. “Sage-ONF is proud to deliver interior materials and solutions of tomorrow to OEMs and consumers, today.”
About Sage Automotive Interiors
Sage Automotive Interiors (www.sageautomotiveinteriors.com ) is one of the world’s leading providers of automotive interior materials—seating, door panel surfaces and headliners—to automotive Original Equipment Manufacturers (OEMs). Global offices and manufacturing locations include the U.S., South America, EMEA and Asia. Sage’s core strengths are consumer research, sustainability and innovative problem solving for the OEM. Sage’s vision is to continually lead the market in design, engineering and technical capability, supported by world-class manufacturing. Sage Automotive Interiors is an Asahi Kasei company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220715005491/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom